Brian Cox on CERN's supercollider

Brian Cox Why we need the explorers

It's a great pleasure to speak after Brian Cox from CERN.

If you take the obese mouse and give it an angiogenesis inhibitor, it loses weight.

Rock star physicist Brian Cox talks about his work on the Large Hadron Collider at CERN. Discussing the biggest of big science in an engaging, accessible way, Cox brings us along on a tour of the massive project.

For example, when the new class of painkillers called Cox 2 inhibitors was introduced, regulators, physicians, and patients were unaware that these drugs could cause heart attacks and strokes. Tens of thousands of innocent patients perhaps more suffered such ADR s before the first two drugs of this class were withdrawn.

Additionally, when some hypoglycemic drugs such as melbine (DMBG) or α glucosidase inhibitor are taken at very onset, patients might happen to side effects like abdominal distension, abdominal pain and diarrhea.

Tasuku Honjo discover the T cell inhibitor receptor PD 1 in 1992, and he initiated the cancer immunotherapy based on it in 2013. His merits and achievements ranked the first of the Annual Top 10 Scientific Breakthroughs of Science .

In tough economic times, our exploratory science programs from space probes to the LHC are first to suffer budget cuts. Brian Cox explains how curiosity driven science pays for itself, powering innovation and a profound appreciation of our existence.

It is especially difficult to attribute an adverse reaction to a drug if the medical event is common in the user s age group or in the condition being treated. Because the risk of heart attacks is high in older people, many of whom have arthritic pain requiring treatment with painkillers, it took six years to link Cox 2 inhibitors to a two to three fold increase in the risk of heart attacks.

We have shown that PARP inhibitors are effective at killing BRCA2 defective breast cancer cells, and that the tumors they cause can fully regress and disappear following treatment with a PARP inhibitor. The next step is to investigate how efficient this treatment is in human patients.

As the International Herald Tribune reports, one aspect of the Chinese government s campaign against corruption is a clampdown on expensive gifts. As a result, according to Jon Cox, an analyst at Kepler Capital Markets, it s no longer acceptable to have a big chunky watch on your wrist.

Recently, my research group, along with researchers in London, provided some real hope for carriers of mutated BRCA1 or BRCA2 genes. Both research teams describe how the use of a chemical inhibitor can kill tumor cells that have either a BRCA1 or BRCA2 gene defect causing hereditary breast cancer.

1 ASG, 2 P 5, 2 P 4, 2 GS (OL), 1 NO, 2 NS

The addition of this inhibitor to intensive chemotherapy has dramatically improved the outlook for these children, increasing the rate of three year event free survival from 35 to 80 . The development of targeted new agents is likely to affect outcomes for other subtypes of childhood cancer, including anaplastic large cell lymphoma and other types of leukemias.

We can divide the 14 by 2, and the 2 by 2, and we get 14 divided by 2 is 7, and 2 divided by 2 is 1.

Article 2, paragraph 2

HIV 2 2 percent

2 NO (2 NOa),

1 D 2, 2 P 5, 4 P 4, 3 P 3, 1 FS, 1 GS (OL), 2 NO, 2 NS, 2 NSa

Case 566 MAL 34 34 (2) (a) (i) 34 (2) (a) (ii) 34 (2) (a) (iii) 34 (2) (a) (iv) 34 (2) (b) (ii)

2 P 2, 25 FS

1 ASG, 2 P 4, 2 GS (OL), 2 NS, 1 NSa

1 ASG, 1 P 5, 2 P 4, 2 GS, 2 NS

1 ASG, 1 P 5, 2 P 4, 2 GS, 2 NS

Wednesday, 2 November 2005, from 12.45 to 2 p.m. in Conference Room 2.

2 pane Gtk 2 file manager

Annex to decision RC 2 2

2 Resolution S 19 2, annex.

8 P 3, 2 P 2,

10 P 3, 2 P 2,

Positions 2 Prefects, 4 Bourgmestres, 1 Lesser admin, 2 Military, 2 Clergy, 5 Others.

Articles of the Optional Protocol 2 and 5, paragraphs 2 (a) and 2 (b)

(8 posts) 1 ASG, 1 P 5, 2 P 4, 2 GS, 2 NS

Articles 16 (2), 47 (9), 75 (2), 76 (9), 84 (2), 287 (8), 298 (6), 312, 313 (1), 319 (1) and 319 (2) articles 2 (2), 2 (5) and 6 (3) of annex II articles 2 and 3 (e) of annex V article 4 (4) of annex VI article 2 (1) of annex VII and article 3 (e) of annex VIII

1 P 3, 2 FS, 2 NS

CTOC COP 2005 2 and Corr.2.

E CN.4 Sub.2 2005 2

E CN.4 Sub.2 2005 2

2 FCCC CP 2001 13 Add.2.

Tel. ( 357 2) 2805928, ( 357 2) 2805932

Tel. ( 20 2) 7950953, ( 20 2) 7922269

2 P 2, 9 FS, 8 GS,

HRI GEN 2 Rev.2 Add.1

E CN.16 2005 2 Corr.2